RESUMO
Las enfermedades pulmonares intersticiales son patologías poco frecuentes en pediatría. Dentro de ellas, se incluyen las disfunciones del metabolismo del surfactante pulmonar, molécula anfipática cuya función es disminuir la tensión superficial y evitar el colapso alveolar. Se presenta el caso de un lactante de 6 meses, en seguimiento por bajo peso, que presentó dificultad respiratoria aguda y cianosis; la radiografía de tórax evidenció infiltrado intersticial, neumomediastino y neumotórax bilateral. Al interrogatorio, surgió antecedente materno de internación al año de vida, con requerimiento de oxigenoterapia prolongada y diagnóstico desconocido; presenta signos de hipoxia crónica. El paciente cursó internación con requerimiento de oxigenoterapia. Se realizaron estudios complementarios en búsqueda de etiología, sin resultados positivos. La tomografía de tórax evidenció opacidades en vidrio esmerilado, engrosamiento del intersticio septal y áreas de atrapamiento aéreo; con resultado de biopsia pulmonar y estudio genético se llegó al diagnóstico de disfunción del metabolismo del surfactante pulmonar.
Interstitial lung diseases are rare in pediatrics. They include dysfunctions in the metabolism of pulmonary surfactant, an amphipathic molecule that reduces surface tension and prevents alveolar collapse. Here we describe the case of a 6-month-old infant controlled for low weight, who presented with acute respiratory distress and cyanosis; his chest X-ray showed interstitial infiltrate, pneumomediastinum, and bilateral pneumothorax. During history-taking, it was noted that his mother had a history of hospitalization at 1 year old with unknown diagnosis, requiring prolonged oxygen therapy; she now shows signs of chronic hypoxia. The patient was hospitalized and required oxygen therapy. Ancillary tests were done to look for the etiology of the condition, with no positive results. A chest computed tomography showed groundglass opacities, thickening of the septal interstitium, and areas of air trapping; based on the results of a lung biopsy and a genetic study, pulmonary surfactant metabolism dysfunction was diagnosed.
Assuntos
Humanos , Lactente , Surfactantes Pulmonares , Doenças Pulmonares Intersticiais/diagnóstico , Doenças Pulmonares Intersticiais/etiologia , Oxigênio , RadiografiaRESUMO
Interstitial lung diseases are rare in pediatrics. They include dysfunctions in the metabolism of pulmonary surfactant, an amphipathic molecule that reduces surface tension and prevents alveolar collapse. Here we describe the case of a 6-month-old infant controlled for low weight, who presented with acute respiratory distress and cyanosis; his chest X-ray showed interstitial infiltrate, pneumomediastinum, and bilateral pneumothorax. During history-taking, it was noted that his mother had a history of hospitalization at 1 year old with unknown diagnosis, requiring prolonged oxygen therapy; she now shows signs of chronic hypoxia. The patient was hospitalized and required oxygen therapy. Ancillary tests were done to look for the etiology of the condition, with no positive results. A chest computed tomography showed groundglass opacities, thickening of the septal interstitium, and areas of air trapping; based on the results of a lung biopsy and a genetic study, pulmonary surfactant metabolism dysfunction was diagnosed.
Las enfermedades pulmonares intersticiales son patologías poco frecuentes en pediatría. Dentro de ellas, se incluyen las disfunciones del metabolismo del surfactante pulmonar, molécula anfipática cuya función es disminuir la tensión superficial y evitar el colapso alveolar. Se presenta el caso de un lactante de 6 meses, en seguimiento por bajo peso, que presentó dificultad respiratoria aguda y cianosis; la radiografía de tórax evidenció infiltrado intersticial, neumomediastino neumotórax bilateral. Al interrogatorio, surgió antecedente materno de internación al año de vida, con requerimiento de oxigenoterapia prolongada y diagnóstico desconocido; presenta signos de hipoxia crónica. El paciente cursó internación con requerimiento de oxigenoterapia. Se realizaron estudios complementarios en búsqueda de etiología, sin resultados positivos. La tomografía de tórax evidenció opacidades en vidrio esmerilado, engrosamiento del intersticio septal y áreas de atrapamiento aéreo; con resultado de biopsia pulmonar y estudio genético se llegó al diagnóstico de disfunción del metabolismo del surfactante pulmonar.
Assuntos
Doenças Pulmonares Intersticiais , Surfactantes Pulmonares , Lactente , Feminino , Humanos , Criança , Doenças Pulmonares Intersticiais/diagnóstico , Doenças Pulmonares Intersticiais/etiologia , Radiografia , OxigênioRESUMO
Abstract Objective: Among the mechanisms proposed for the development of bronchopulmonary dysplasia is the increase in the pulmonary inflammatory process and oxidative stress. Thus, the control of this process may result in improvements in bronchopulmonary dysplasia-related outcomes. This study aims to analyze the current scientific evidence regarding the use of budesonide, a potent anti-inflammatory drug, associated with a pulmonary surfactant to prevent bronchopulmonary dysplasia. Methods: A systematic review of the literature was performed on the Embase and MEDLINE platforms, and studies that compared budesonide with pulmonary surfactant versus pulmonary surfactant for treating respiratory distress syndrome were included. The primary outcome was a reduction in bronchopulmonary dysplasia or death. Results: Four randomized clinical trials and two observational studies were included in this systematic review. Three of the randomized clinical trials found a reduction in bronchopulmonary dysplasia or death in the use of budesonide with the surfactant, all the other studies (1 clinical trial and 2 observational studies) found no statistical differences between the groups for the primary outcomes. The three main studies showed a reduction in the primary outcome; however, all studies showed great heterogeneity regarding the type of surfactant (poractant or beractant) and the method of administration. Conclusion: Robust clinical studies, in a heterogeneous population, using porcine surfactant associated with budesonide, with administration by a minimally invasive technique are necessary for there to be a recommendation based on scientific evidence for its widespread use.
RESUMO
OBJECTIVE: Among the mechanisms proposed for the development of bronchopulmonary dysplasia is the increase in the pulmonary inflammatory process and oxidative stress. Thus, the control of this process may result in improvements in bronchopulmonary dysplasia-related outcomes. This study aims to analyze the current scientific evidence regarding the use of budesonide, a potent anti-inflammatory drug, associated with a pulmonary surfactant to prevent bronchopulmonary dysplasia. METHODS: A systematic review of the literature was performed on the Embase and MEDLINE platforms, and studies that compared budesonide with pulmonary surfactant versus pulmonary surfactant for treating respiratory distress syndrome were included. The primary outcome was a reduction in bronchopulmonary dysplasia or death. RESULTS: Four randomized clinical trials and two observational studies were included in this systematic review. Three of the randomized clinical trials found a reduction in bronchopulmonary dysplasia or death in the use of budesonide with the surfactant, all the other studies (1 clinical trial and 2 observational studies) found no statistical differences between the groups for the primary outcomes. The three main studies showed a reduction in the primary outcome; however, all studies showed great heterogeneity regarding the type of surfactant (poractant or beractant) and the method of administration. CONCLUSION: Robust clinical studies, in a heterogeneous population, using porcine surfactant associated with budesonide, with administration by a minimally invasive technique are necessary for there to be a recommendation based on scientific evidence for its widespread use.
Assuntos
Displasia Broncopulmonar , Surfactantes Pulmonares , Síndrome do Desconforto Respiratório do Recém-Nascido , Humanos , Animais , Suínos , Recém-Nascido , Budesonida/uso terapêutico , Displasia Broncopulmonar/tratamento farmacológico , Displasia Broncopulmonar/prevenção & controle , Tensoativos/uso terapêutico , Ensaios Clínicos Controlados Aleatórios como AssuntoRESUMO
INTRODUCTION: In inflammatory respiratory diseases, the imbalance between proteases and endogenous protease inhibitors leads to an exacerbated activity of human neutrophil elastase (a protease that destroys the extracellular matrix and stimulates proinflammatory cytokine release). Elastase is considered a target in the search for therapeutic treatments for inflammatory respiratory diseases. Pulmonary surfactant is a promising product for this purpose, because in addition to its biophysical function, it has anti-inflammatory properties. OBJECTIVE: Evaluate effect of the Cuban porcine pulmonary surfactant (Surfacen), the rCmPI-II elastase inhibitor, and the Surfacen/rCmPI-II combination on activated neutrophil elastase activity in vitro, and determine if Surfacen's interface property changes in the presence of the inhibitor. METHODS: The anti-elastase effect of Surfacen, rCmPI-II and the Surfacen/rCmPI-II combination was evaluated in an in vitro model of activated neutrophils, previously purified from the blood of healthy subjects. The cells were stimulated with LPS/fMLP and were incubated with different concentrations of Surfacen, rCmPI-II and the Surfacen/rCmPI-II combination. Elastase activity was measured. The interface property was determined on a Langmuir surface balance. The new index, called the abdominal adipose deposit index, was obtained by multiplying the subcutaneous fat thickness by visceral fat thickness, both measured by ultrasound. A cutoff point was established that facilitated discernment of an unhealthy phenotype: normal weight but metabolically obese, a cardiometabolic risk factor. RESULTS: Surfacen at 10 mg/mL inhibited 71% of stimulated neutrophil elastase activity. rCmPI-II at 0.1 µM reduced 20% of elastase activity; at 200 µM-the maximum concentration evaluated-inhibition was 68%. Both products had a dose-dependent effect. The Surfacen/inhibitor combination (0.5 mg/mL/80 µM) did not affect the surfactant interface property or the inhibitory activity of rCmPI-II against human neutrophil elastase. CONCLUSIONS: Surfacen and the rCmPI-II inhibitor have an anti-elastase effect on an activated neutrophil model. rCmPI-II does not affect Surfacen's interface property and, therefore, both can be evaluated for combined use in treating inflammatory lung diseases.
Assuntos
Elastase de Leucócito , Surfactantes Pulmonares , Animais , Humanos , Antivirais , Elastase de Leucócito/farmacologia , Neutrófilos , Inibidores de Proteases/farmacologia , Surfactantes Pulmonares/farmacologia , SuínosRESUMO
Resumen Introducción: Los trastornos genéticos que afectan la homeostasis del surfactante pulmonar son una causa importante del síndrome de dificultad respiratoria en el recién nacido a término y de enfermedad pulmonar intersticial difusa en niños. El transportador ABCA3 (ATP binding cassette A3) interviene en la producción normal del surfactante que recubre el interior de las paredes alveolares y funciona como agente tensioactivo. Caso clínico: Recién nacido a término que presentó dificultad respiratoria a los 3 días de vida y requirió ventilación mecánica. Los estudios para determinar otras causas de enfermedad pulmonar fueron negativos. Se realizó una biopsia de pulmón para realizar estudios de microscopía óptica y microscopía electrónica. Esta última mostró pequeños cuerpos lamelares anómalos, además de condensaciones electrodensas periféricas, características de las mutaciones del transportador ABCA3. Se inició tratamiento con pulsos de metilprednisolona, hidroxicloroquina, azitromicina y corticoides inhalados a dosis altas, y la respuesta clínica y radiológica fue favorable durante el seguimiento. Conclusiones: La correlación de las características clínicas y de las imágenes (tomografía y microscopía electrónica) puede ser útil para el diagnóstico de la disfunción del surfactante pulmonar, especialmente en los países de bajos y medianos recursos que no disponen de estudios genéticos para determinar las diferentes mutaciones del transportador ABCA3. Este es uno de los primeros casos reportados en Perú con respuesta adecuada al tratamiento y evolución favorable durante el seguimiento.
Abstract Background: Genetic disorders affecting pulmonary surfactant homeostasis are a major cause of respiratory distress syndrome in full-term newborn and childhood interstitial lung disease. The ABCA3 transporter (ATP binding cassette A3) intervenes in the normal production of surfactant that covers the interior of alveolar walls and plays a fundamental role as a surfactant. Case report: Male term newborn who presented respiratory distress 3 days after birth and required mechanical ventilation. Studies to determine other causes of lung disease were negative. Lung biopsy was performed for the study with light microscopy and electron microscopy. Electron microscopy showed small abnormal lamellar bodies in addition to peripheral electrodense condensations characteristic of ABCA3 transporter mutation. Treatment was started with pulses of methylprednisolone, hydroxychloroquine, azithromycin, and high-dose inhaled corticosteroids, finding a favorable clinical and radiological response to follow-up. Conclusions: Correlation of clinical characteristics and images (tomography and electron microscopy) can be useful for the diagnosis of lung surfactant dysfunction, especially in low and medium-income countries where genetic studies to determine the different ABCA3 transporter mutations are not available. This is one of the first cases reported in Peru with an adequate response to treatment and favorable evolution to follow-up.
Assuntos
Humanos , Doenças Pulmonares Intersticiais , Peru , Tensoativos , Transportadores de Cassetes de Ligação de ATP/genéticaRESUMO
RESUMO Objetivo: Investigar a influência do manejo da síndrome do desconforto respiratório sobre parâmetros clínicos e ecocardiográficos de avaliação hemodinâmica em recém-nascidos ≤ 32 semanas. Métodos: Foram avaliados prospectivamente 33 recém-nascidos ≤ 32 semanas, submetidos à ventilação mecânica invasiva. A necessidade de surfactante exógeno e os parâmetros clínicos e ecocardiográficos nas primeiras 24 horas de vida foram detalhadas nesse grupo de pacientes. Resultados: O valor da pressão média de vias aéreas foi significativamente maior nos recém-nascidos que necessitaram de inotrópicos [10,8 (8,8 - 23) cmH2O versus 9 (6,2 - 12) cmH2O; p = 0,04]. Houve correlação negativa entre pressão média de vias aéreas e integral velocidade-tempo da artéria pulmonar (r = -0,39; p = 0,026), débito do ventrículo direito (r = -0,43; p = 0,017) e medidas da excursão do plano do anel tricúspide (r = -0,37; p = 0,036). Verificou-se correlação negativa entre o número de doses de surfactante exógeno e: débito de ventrículo direito (r = -0,39; p = 0,028) e a integral velocidade-tempo da artéria pulmonar (r = -0,35; p = 0,043). Conclusão: Nos recém-nascidos ≤ 32 semanas em ventilação mecânica invasiva, elevações de pressão média de vias aéreas e do número de doses de surfactante correlacionam-se com piora da função cardíaca precoce. Aparentemente, o manejo mais agressivo da síndrome do desconforto respiratório contribui para a instabilidade hemodinâmica desses pacientes.
ABSTRACT Objective: To investigate the influence of respiratory distress syndrome management on clinical and echocardiographic parameters used for hemodynamic evaluation in ≤ 32- week newborns. Methods: Thirty-three ≤ 32-week newborns were prospectively evaluated and subjected to invasive mechanical ventilation. The need for exogenous surfactant and clinical and echocardiographic parameters in the first 24 hours of life was detailed in this group of patients. Results: The mean airway pressure was significantly higher in newborn infants who required inotropes [10.8 (8.8 - 23) cmH2O versus 9 (6.2 - 12) cmH2O; p = 0.04]. A negative correlation was found between the mean airway pressure and velocity-time integral of the pulmonary artery (r = -0.39; p = 0.026), right ventricular output (r = -0.43; p = 0.017) and measurements of the tricuspid annular plane excursion (r = -0.37; p = 0.036). A negative correlation was found between the number of doses of exogenous surfactant and the right ventricular output (r = -0.39; p = 0.028) and pulmonary artery velocity-time integral (r = -0.35; p = 0.043). Conclusion: In ≤ 32-week newborns under invasive mechanical ventilation, increases in the mean airway pressure and number of surfactant doses are correlated with the worsening of early cardiac function. Therefore, more aggressive management of respiratory distress syndrome may contribute to the hemodynamic instability of these patients.
Assuntos
Humanos , Masculino , Feminino , Recém-Nascido , Síndrome do Desconforto Respiratório do Recém-Nascido/fisiopatologia , Síndrome do Desconforto Respiratório do Recém-Nascido/diagnóstico por imagem , Ecocardiografia , Hemodinâmica , Respiração Artificial , Síndrome do Desconforto Respiratório do Recém-Nascido/terapia , Fatores de Tempo , Recém-Nascido Prematuro , Estudos Prospectivos , Fatores Etários , Idade GestacionalRESUMO
RESUMEN Fundamento: el primer reporte de la eficacia de un surfactante pulmonar exógeno en el tratamiento de la enfermedad de membrana hialina data de 1980. A partir de ese hallazgo diferentes grupos de investigadores en todo el mundo dedican sus esfuerzos al desarrollo de surfactantes pulmonares ya sean naturales o sintéticos. Objetivo: desarrollar una estrategia para la evaluación de la eficacia y seguridad de Surfacen® en el tratamiento, que permitiera su registro e introducción a la práctica habitual. Métodos: para demostrar la eficacia y seguridad de Surfacen® en el tratamiento del síndrome de dificultad respiratoria en recién nacidos pretérmino, se realizaron ensayos clínicos y la fármaco-vigilancia. En otras indicaciones como el síndrome de dificultad respiratoria aguda en niños y adultos; se ejecutaron ensayos clínicos (fase II, III y IV). En todos los ensayos se siguió la metodología establecida para cada fase. Resultados: el Surfacen® demostró su eficacia al mejorar la oxigenación, las variables ventilatorias, las radiográficas, la evolución clínica que contribuyó a reducir la mortalidad en recién nacidos pretérmino, con un perfil de seguridad similar al resto de surfactantes pulmonares comercializados a nivel internacional. La terapia con Surfacen® fue eficaz al reducir la mortalidad en niños (esta última no en adultos), demostró ser bien tolerada y segura al notificarse un número reducido de eventos adversos relacionados con su administración. Los días de estancia en las unidades de cuidados intensivos y días de ventilación mecánica no se modificaron con el esquema de tratamiento evaluado. Conclusiones: se registró Surfacen® para las indicaciones terapéuticas estudiadas y se introdujo en la práctica clínica habitual al contribuir a reducir la mortalidad en niños.
ABSTRACT Background: the first report of the efficacy of an exogenous pulmonary surfactant in the treatment of the membrane hyaline illness dates back to 1980. From this finding, different groups of investigators worldwide dedicate their efforts to the development of pulmonary surfactants either natural or synthetic. Objective: to develop a strategy for the evaluation of the efficacy and safety of Surfacen® in the treatment of respiratory distress syndrome that would allow its registration and introduction to normal practice. Methods: to demonstrate the efficacy and safety of Surfacen® in the treatment of RDS in preterm infants, clinical trials and the pharmaco-vigilance were conducted. In other indications such as acute RDS in children and adults; clinical trials (phase II, III and IV) were conducted. In all the trials, the methodology established for each phase was followed. Results: Surfacen® demonstrated its efficacy by improving oxygenation, ventilation variables, radiographic ones, clinical evolution and contributed to reduce mortality in preterm infants, with a safety profile similar to the rest of commercially available pulmonary surfactants internationally. Surfacen® therapy proved to be effective in improving oxygenation, ventilation variables, radiographic, clinical evolution, contributed to reduce mortality in children, (the latter not in adults) and proved to be well tolerated and safe to notify a reduced number of adverse events related to its administration. The days of stay in the intensive care units and days of mechanical ventilation were not modified with the treatment scheme evaluated. Conclusions: Surfacen® was registered for the therapeutic indications studied and introduced in routine clinical practice contributing to reduce mortality in children.
RESUMO
Resumen: En la era de la búsqueda de estrategias ventilatorias mínimamente invasivas, la administración profiláctica de surfactante con técnicas sencillas, que no requieren elevada destreza y que pueden ser realizadas en ámbitos de baja complejidad, deben ser investigadas para potencialmente disminuir la morbilidad y mortalidad del pretérmino. Se reporta el uso de surfactante en la orofaringe de cuatro recién nacidos de muy bajo peso (promedio de peso de 1.236 g y 28 semanas de edad gestacional), y concomitante colocación de presión positiva continua por pieza nasal antes de la primera inspiración extrauterina manteniendo el cordón intacto. No se registraron efectos adversos y la aspiración gástrica posterior demostró que el surfactante fue inspirado a los pulmones del recién nacido. La administración de surfactante orofaríngeo es una técnica innovadora, segura, factible y reproducible. A la vez que minimizamos los riesgos de posible iatrogenia por la técnica utilizada, facilitamos una transición cardiovascular más estable, manteniendo la circulación fetoplacentaria.
Summary: In the era of minimally invasive ventilatory procedures, the prophylactic administration of surfactant using simple techniques that can be performed in low complexity settings, should be researched as a tool to potentially reduce preterm morbidity and mortality. We report the use of oropharyngeal surfactant in 4 very low birth weight newborns (average birth weight 1236g and 28 weeks of gestational age) and of continuous positive airway pressure before the first intrauterine inspiration and keeping an intact umbilical cord. No adverse effects happened, and the aspiration of gastric residual confirmed that surfactant had reached the lungs. The administration of oropharyngeal surfactant is an innovative, safe, feasible and reproducible technique. It minimizes the risks of possible iatrogenesis due to the technique used, and it also facilitates a more stable cardiovascular transition, maintaining the fetus' placental circulation.
Resumo: Na era da procura de técnicas ventilatórias minimamente invasivas, a administração profilática de surfactante utilizando técnicas simples, que não requerem muita destreza e que pode ser realizada em contextos de baixa complexidade, deve ser pesquisada para reduzir potencialmente a morbidade e mortalidade dos pré-termos. Reportamos o uso de surfactante na orofaringe em 4 recém-nascidos com baixo peso ao nascimento (peso médio de 1,236 g e 28 semanas de idade gestacional), e colocação concomitante de pressão positiva contínua por adaptador nasal, antes da primeira inspiração extrauterina e mantendo o cordão umbilical intacto. Não houve efeitos adversos e o aspirado gástrico subsequente mostrou que o surfactante foi inspirado e observado nos pulmões dos recém-nascidos. O surfactante de administração orofaríngea é uma técnica inovadora, segura, viável e reprodutível. Minimiza os riscos iatrogênicos eventuais devido à técnica utilizada, à vez que proporciona uma transição cardiovascular mais estável porque mantém a circulação da placenta fetal.
RESUMO
La Proteinosis Alveolar Pulmonar (PAP) es una enfermedad poco frecuente, caracterizada por la acumulación de material lipoproteico derivado del surfactante pulmonar al interior de los alvéolos por una falla de depuración de este material por los macrófagos alveolares, siendo la causa más frecuente de esta disfunción la acción bloqueadora producida por anticuerpos anti factor estimulante de colonias de granulocitos y macrófagos (GM-CSF) lo que lleva a un deterioro del intercambio gaseoso. La evolución es variable abarcando desde la resolución espontánea hasta la insuficiencia respiratoria grave y la muerte. Se describen tres formas de PAP: Genética, secundaria y autoinmune (antes primaria o idiopática) siendo esta última la más frecuente en adultos. Clínicamente, se manifiesta por disnea, tos seca e hipoxemia que pueden ser progresivas. En la radiografía de tórax se encuentran opacidades bilaterales y la tomografía computarizada de tórax de alta resolución (TACAR) muestra vidrio esmerilado con sobre posición de engrosamiento septal intra e interlobulillar, patrón conocido como "crazy paving". El diagnóstico se basa en la clínica y en el lavado broncoalveolar con material PAS positivo. La biopsia quirúrgica es confirmatoria. El tratamiento clásico es el lavado pulmonar total (LPT) para remover el contenido alveolar. Otras alternativas son la administración de GM-CSF subcutáneo o inhalado, plasmaferesis y rituximab, cuyos resultados son variables. Diferentes autores han modificado la forma del LPT y combinado los diferentes métodos de tratamiento con el fin de obtener resultados más rápidos y efectivos.
Pulmonary Alveolar Proteinosis (PAP) is a rare disease characterized by the accumulation of surfactant derived lipoproteinaceous material filling the alveoli, secondary to failure of its clearance by macrophages. Most of the patients are adults that have auto antibodies directed to Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF). The evolution is towards disturbed gaseous exchange with a wide spectrum of disease from spontaneous recovery to death. There are three forms of PAP: genetic, secondary and autoimmune. Symptoms are scarce and patients may present with dyspnea, dry cough and hypoxemia. Chest X ray shows bilateral opacities and thorax CT depicts ground glass opacities surrounded by septal widening, the so called "crazy paving" pattern. Diagnosis is made on clinical and radiological grounds and confirmed by PAS positive staining of bronchoalveolar lavage material or surgical lung biopsy. Accepted treatment is whole lung lavage (WLL) with saline. Alternatives are subcutaneous or inhaled GM-CSF, Plasmapheresis or Rituximab, and even modification of the method of WLL and combination of different manner of treatment.
Assuntos
Humanos , Proteinose Alveolar Pulmonar/diagnóstico , Proteinose Alveolar Pulmonar/terapia , Proteinose Alveolar Pulmonar/etiologia , Surfactantes Pulmonares/uso terapêutico , Fator Estimulador de Colônias de Granulócitos e Macrófagos , Plasmaferese , Lavagem Broncoalveolar , Rituximab/uso terapêuticoRESUMO
Abstract The treatment with exogenous surfactant reduces mortality and the risk of complications in preterm newborns with Respiratory Distress Syndrome. Higher usage levels have been associated with individual and institutional factors. The study aimed to identify these factors associated with use of this technology in 16 public Brazilian Neonatal Units using logistic multilevel analysis. In a sample of 630 newborns the use at some time was 82.6%. Only 24.7% made use of this technology up to two hours after birth. An intraclass correlation of 0.30 showed that 30% of the variance in the use of exogenous surfactant could be assigned to the contextual level. In the final model, a greater severity score (SNAPPE-II) was associated with increased surfactant use (OR = 2.64), whereas being small for gestational age (SGA) (OR = 0.59) was associated with lower use of this technology. At the contextual level the number of beds in the unit >15 (OR = 5.86), units with higher complexity (OR = 1.73) or units with implemented Kangaroo Mother Care (OR = 2.91), especially units in Rio de Janeiro state (OR = 16.17) were associated with greater surfactant use. Although individual clinical features explained most of the variation in the use of this technology, factors linked to the institution were also of utmost importance.
Resumo O tratamento com surfactante exógeno reduz a mortalidade e o risco de complicações em recém-nascidos com Síndrome de Angústia Respiratória. Maiores níveis de utilização dessa tecnologia têm sido associados tanto a fatores individuais como institucionais. O estudo teve como objetivo identificar esses fatores em 16 unidades neonatais públicas brasileiras usando análise multinível. De 630 recém-nascidos, 82,6% usaram a tecnologia em algum momento. Apenas 24,7% fizeram uso até duas horas após o nascimento. Uma correlação intraclasse de 0,30 mostrou que 30% da variação no uso podem ser atribuídos ao nível contextual. No modelo final, um escore de gravidade maior (SNAPPE-II) foi associado com aumento do uso de surfactante (OR = 2,64), enquanto que ser pequeno para a idade gestacional (PIG) (OR = 0,59) foi associado a um menor uso dessa tecnologia. No nível contextual o número de leitos na unidade > 15 (OR = 5,86), as unidades com mais alta complexidade (OR = 1,73) ou unidades com Método Canguru implementado (OR = 2,91), especialmente unidades no estado do Rio de Janeiro (OR = 16,17), foram associados com uma maior utilização de surfactante. Embora características individuais tenham explicado a maior parte da variação no uso desta tecnologia, fatores ligados à instituição também foram de extrema importância.
Assuntos
Humanos , Feminino , Gravidez , Recém-Nascido , Adulto , Adulto Jovem , Síndrome do Desconforto Respiratório do Recém-Nascido/tratamento farmacológico , Surfactantes Pulmonares/administração & dosagem , Unidades de Terapia Intensiva Neonatal , Método Canguru , Síndrome do Desconforto Respiratório do Recém-Nascido/fisiopatologia , Índice de Gravidade de Doença , Brasil , Recém-Nascido Prematuro , Modelos Logísticos , Prevalência , Idade Gestacional , Análise MultinívelRESUMO
BACKGROUND: Pulmonary surfactant is a complex mixture of lipids and proteins. Mutations in surfactant protein-C, surfactant protein-D, and adenosine triphosphate-binding cassette subfamily A member 3 have been related to surfactant dysfunction and neonatal respiratory failure in full-term babies. Adenosine triphosphate-binding cassette subfamily A member 3 facilitates the transfer of lipids to lamellar bodies. We report the case of patient with a homozygous intronic ABCA3 mutation. CASE PRESENTATION: We describe a newborn full-term Colombian baby boy who was the son of non-consanguineous parents of mixed race ancestry (Mestizo), who was delivered with severe respiratory depression. Invasive treatment was unsuccessful and diagnosis was uncertain. Exons 4 and 5 of the SP-C gene showed heterozygous Thr138Asn polymorphism and homozygous Asn186Asn polymorphism respectively. At intron 25 at position -98 from exon 26 a homozygous C>T transition mutation was detected in ABCA3 gene. CONCLUSIONS: The clinical presentation and the histopathological findings of this case are consistent with a case of neonatal respiratory failure due to surfactant deficiency. Analysis of the five coding SP-C exons does not support surfactant deficiency. An analysis of the mutation IVS25-98 T was performed and a homozygous mutation responsible for our case's neonatal respiratory failure was detected. The findings suggest an autosomic recessive pattern of inheritance. Genetic counseling was provided and the relatives are now informed of the recurrence risks and treatment options.
RESUMO
Introducción: el síndrome de dificultad respiratoria aguda (SDRA) es una enfermedad nosológica asociada con una alta morbilidad y mortalidad. Objetivo: determinar los eventos adversos (EA) asociados a la terapia con surfactante pulmonar (SURFACEN®) en adultos con SDRA. Métodos: se incluyeron 48 pacientes adultos entre 18 y 75 años con SDRA en un ensayo clínico fase II, controlado, aleatorizado y multicéntrico. El grupo A con 24 pacientes, recibió surfactante pulmonar cada ocho horas, durante tres días, en dosis de 100 mg totales, junto al tratamiento estándar (oxigenación y ventilación mecánica). El grupo B, también con 24 pacientes, recibió el tratamiento estándar. Se identificó y cuantificó la aparición de eventos adversos, así como la gravedad, seriedad y relación de causalidad con respecto al fármaco desde la inclusión del paciente en el estudio hasta el egreso de la unidad de cuidados intensivos (UCI). Resultados: el 56, 25 % de los pacientes incluidos presentó algún evento adverso: 14 (29, 17 %) en el grupo A y 13 (27, 08 %) en el B. El 42, 37 % de estos EA se manifestaron con intensidad moderada; el 39, 39 % resultó reversible y el 92, 59 % tuvo causalidad remota respecto al surfactante. La fiebre fue el EA que se reportó con mayor frecuencia. Conclusiones: el surfactante pulmonar (SURFACEN®) junto al tratamiento estándar en adultos con SDRA es seguro.
Introduction: acute respiratory distress syndrome is a nosologic disease associated to a high mortality and morbidity. Objective: to determine the adverse events associated to the therapy with pulmonary surfactant (SURFACEN®) in adults with acute respiratory distress syndrome. Methods: a randomized and multicentric clinical trial stage II was conducted in 48 adult patients between 18 and 75 years old. The group A, that included 24 patients, received doses of 100 total milligrams of pulmonary surfactant every eight hours for three days, along with the standard treatment (oxygenation and mechanical ventilation). The group B, also with 24 patients, received the standard treatment. The appearance of adverse events was identified and quantified, as well as the seriousness and the causality regarding the medicine from the inclusion of the patient in the study to the discharge from the intensive care unit. Results: the 56, 25 % of the patients included in the study presented an adverse event: 14 (29, 17 %) in the group A and 13 (27, 08 %) in the group B. The 42, 37 % of these adverse events appeared with moderate intensity; the 39, 39 % were reversible and the 92, 59 % had a remote causality regarding the surfactant. Fever was the most frequent adverse event reported. Conclusions: pulmonary surfactant (SURFACEN®), along with the standard treatment in adults with acute respiratory distress syndrome, is safe.
RESUMO
Fundamento: existen discrepancias con respecto al uso de surfactante en la bronconeumonía del recién nacido. Objetivo: evaluar el comportamiento de los recién nacidos con bronconeumonía de inicio temprano tratados con surfactante exógeno. Métodos: se realizó un estudio multicéntricos, abierto, no aleatorizado ni controlado, en 39 recién nacidos pretérminos con bronconeumonía de inicio temprano tratados con surfactante exógeno. Se estudió la edad gestacional, el peso al nacer y el tiempo de estadía en la unidad de cuidados intensivos neonatales, la relación PaO²/FiO², el tiempo en ventilación mecánica, las complicaciones del soporte ventilatorio y la mortalidad según número de dosis de surfactante exógeno y uso de esteroides prenatales para lo que se calcularon, las frecuencias absolutas y relativas, las medias y ji cuadrado. Resultados: la necesidad de administrar un mayor número de dosis se asoció a menor relación PaO²/FiO² (p=0,0103), se obtuvieron valores adecuados con la primera y segunda dosis. El uso de esteroides prenatales se asoció a un menor tiempo en ventilación mecánica (p=0,0474), a valores mayores de la relación PaO²/FiO² (p=0,0162) y a una menor mortalidad (p=0,0076). No se halló asociación estadística en las complicaciones relacionadas con la ventilación. Conclusiones: los pacientes que requirieron mayor número de dosis de surfactante tuvieron una respuesta ventilatoria desfavorable y mayor mortalidad. El uso de esteroides prenatales favoreció una mejor respuesta ventilatoria y menor mortalidad. Puede ser beneficiosa la combinación del uso prenatal de esteroides y surfactante exógeno en pretérminos con bronconeumonía de inicio temprano.
Background: there are disagreements about the use of surfactant in bronchopneumonia in newborns. Objective: to evaluate the behaviour of newborns with early bronchopneumonia treated with exogenous surfactant. Methods: an open, multicentric, non-randomized or controlled study was conducted in 39 preterm newborns with early bronchopneumonia treated with exogenous surfactant. The gestation age, the birth weight and the stay time in the neonatal intensive care unit, the relation PaO2/FiO2, the mechanical ventilation time, the complications of ventilatory support and the mortality according to the number of doses of exogenous surfactant and the use of prenatal steroids were studied. The absolute and relative frequencies, the average and the chi-squared test were calculated. Results: the need of administrating a greater number of doses was associated to a lower relation PaO²/FiO² (p=0,0103). Adequate values were obtained with the first and the second doses. The use of prenatal steroids was associated to a lesser time with mechanical ventilation (p=0,0474), to greater values of the relation PaO²/FiO² (p=0,0162) and to a lower mortality (p=0,0076). No statistical association was found in the complications related to ventilation. Conclusions: those patients who required a greater number of doses of surfactant had an unfavorable ventilatory response and a greater mortality. The use of prenatal steroids favoured a better ventilatory response and a lower mortality. The combination of prenatal steroids and exogenous surfactant can be beneficial in preterm newborns with early bronchopneumonia.
RESUMO
Fundamento: las atelectasias son un estado de colapso y falta de aire en todo el pulmón o en una zona del mismo. Una vez establecido el diagnóstico de colapso bronquial, el tratamiento debe orientarse directamente a la causa de la obstrucción y a la infección que habitualmente concomita. Objetivo: utilizar como estrategia de tratamiento el lavado broncoalveolar con surfactante exógeno (Surfacen®) unido a la fisioterapia respiratoria. Caso clínico: se presenta un caso de una paciente de 16 años de edad con el antecedente patológico personal de Epilepsia desde los dos años de vida bajo tratamiento con valproato de sodio, que ingresa en la unidad de cuidados intensivos del hospital pediátrico Dr. Eduardo Agramonte Piña, a la que se diagnostica por clínica, radiología y gasometría el síndrome de dificultad respiratoria aguda resultante de una causa pulmonar directa, al quinto día de tratamiento presenta compromiso respiratorio agudo con caída brusca de la oxigenación y se diagnostica radiológicamente una atelectasia masiva del pulmón izquierdo, se le realizó lavado broncoalveolar amplio con solución salina al 0,9 % y luego se instiló surfactante exógeno en dosis de 100 mg diluidos en 10 mL de agua para inyección, dos veces al día, administrado por vía intrabronquial. Luego del segundo lavado broncoalveolar y la kinesioterapia respiratoria, se logra la expansión total de la zona colapsada y recuperación notable de los parámetros de oxigenación. La radiografía reveló una mejoría evidente luego del tratamiento. Se retira la ventilación mecánica cinco días después de esta complicación, mantuvo buena evolución posterior. Conclusiones: la aplicación del lavado broncoalveolar con surfactante exógeno mejoró el compromiso de oxigenación que ocasiona la atelectasia masiva y permitió una rápida evolución radiográfica en la paciente, así como la disminución de los parámetros ventilatorios.
Background: atelectasis is a collapse state and shortness of breath in part or all of one lung. Once the diagnosis of bronchial collapse is established, the treatment must be directed towards the find of the cause of obstruction and the infection that is usually concomitant. Objective: to use bronchoalveolar lavage with exogenous surfactant (Surfacen®), along with respiratory physiotherapy as treatment. Clinical case: the case of a sixteen-year-old female patient with a personal-pathological history of epilepsy since she was two years old is presented. The patient was under treatment with valproate sodium. She is admitted in the intensive care unit of Dr. Eduardo Agramonte Piña Pediatric Hospital. The patient is diagnosed clinically, radiologically and gasometrically as having respiratory distress syndrome of a direct pulmonary cause. On the fifth day of treatment the patient presented acute respiratory problems with sudden oxygenation fall and is diagnosed radiologically as having massive atelectasis of the left lung. She underwent a wide bronchoalveolar lavage with 9 % saline solution and then the instillation of exogenous surfactant in 100 mg doses diluted in 10 ml of water per injection administered intrabronchially twice a day. After the second bronchoalveolar lavage and the respiratory kinesiotherapy, the total expansion of the collapsed area and a notable improvement of the oxygenation parameters were achieved. The mechanical ventilation was moved five days after the complication. The patient kept a good subsequent progress. Conclusions: the application of bronchoalveolar lavage with exogenous surfactant improved the oxygenation problem that causes massive atelectasis and allowed a rapid radiographic progress in the patient, as well as the decrease of the ventilatory parameters.
RESUMO
Introducción. La presión positiva continua en la vía aérea ( Continuous Positive Airway Pressure , CPAP) es útil en prematuros de 28 a 32 semanas de gestación con síndrome de dificultad respiratoria, pero no se ha precisado si es mejor que la respiración mecánica asistida después de la administración precoz de surfactante pulmonar. Objetivo. Comparar la incidencia de eventos adversos en prematuros de 28 a 32 semanas de gestación con síndrome de dificultad respiratoria atendidos con surfactante y respiración mecánica asistida o CPAP de burbuja. Materiales y métodos. Se atendieron 147 neonatos con respiración mecánica asistida y 176 con CPAP, ninguno de los cuales presentaba asfixia perinatal o apnea. Resultados. La incidencia de fracaso de la CPAP fue de 6,5 % (IC 95% 11,3-22,8 %). Fallecieron 29 pacientes, 7 de los cuales habían recibido CPAP (4,0 %) y, 22, respiración mecánica asistida (15,0 %; p<0,001). El riesgo relativo (RR) de morir de quienes recibieron CPAP, comparado con el de quienes recibieron respiración mecánica asistida, fue de 0,27 (IC 95% 0,12-0,61), pero, al ajustar por los factores de confusión, el uso de CPAP no implicó mayor riesgo de morir (RR=0,60; IC 95% 0,29-1,24). La letalidad con respiración mecánica asistida fue de 5,70 (IC 95% 3,75-8,66) muertes por 1.000 días-paciente, mientras que con CPAP fue de 1,37 (IC 95% 0,65-2,88; p<0,001). La incidencia de neumopatía crónica fue menor con CPAP (RR=0,71, IC 95% 0,54-0,96), al igual que la de hemorragia cerebral (RR=0,28; IC 95% 0,09-0,84) y la de sepsis (RR=0,67; IC 95% 0,52-0,86), pero fue similar en cuanto a escapes de aire (RR=2,51; IC 95% 0,83-7,61) y enterocolitis necrosante (RR=1,68; IC 95% 0,59-4,81). Conclusión. La incidencia de neumopatía crónica, hemorragia ventricular y sepsis es menor con el uso de CPAP.
Introduction: Continuous positive airway pressure (CPAP) is useful in low birth weight infants with respiratory distress, but it is not known if it is a better alternative to mechanical ventilation after early pulmonary surfactant administration. Objective: To compare the incidence of adverse events in 28 to 32-week newborns with respiratory distress managed with mechanical ventilation or CPAP after early surfactant administration. Materials and methods: In total, 176 newborns were treated with CPAP and 147 with mechanical ventilation, all with Apgar scores >3 at five minutes and without apnea. Results: The incidence of CPAP failure was 6.5% (95% CI: 11.3-22.8%); 29 patients died: 7 with CPAP (4.0%) and 22 with mechanical ventilation (15.0%, p<0.001). The relative risk of dying with CPAP versus mechanical ventilation was 0.27 (95% CI: 0.12-0.61), but after adjusting for confounding factors, CPAP use did not imply a higher risk of dying (RR=0.60; 95% CI: 0.29-1.24). Mechanical ventilation fatality rate was 5.70 (95% CI: 3.75-8.66) deaths/1,000 days-patient, while with CPAP it was 1.37 (95% CI: 0.65-2.88, p<0.001). Chronic lung disease incidence was lower with CPAP than with mechanical ventilation (RR=0.71; 95% CI: 0.54-0.96), as were intracranial hemorrhage (RR=0.28, 95% CI: 0.09-0.84) and sepsis (RR=0.67; 95%CI: 0.52-0.86), and it was similar for air leaks (RR=2.51; 95% CI: 0.83-7.61) and necrotizing enterocolitis (RR=1.68, 95% CI: 0.59-4.81). Conclusion: CPAP exposure of premature infants with respiratory distress syndrome is protective against chronic lung disease, intraventricular hemorrhage and sepsis compared to mechanical ventilation. No differences were observed regarding air leak syndrome or death.
Assuntos
Adulto , Feminino , Humanos , Recém-Nascido , Masculino , Gravidez , Produtos Biológicos/uso terapêutico , Pressão Positiva Contínua nas Vias Aéreas/métodos , Doenças do Prematuro/terapia , Respiração Artificial , Síndrome do Desconforto Respiratório do Recém-Nascido/terapia , Índice de Apgar , Doença Crônica , Comorbidade , Hemorragia Cerebral/epidemiologia , Hemorragia Cerebral/prevenção & controle , Enterocolite Necrosante/epidemiologia , Idade Gestacional , Doença da Membrana Hialina/tratamento farmacológico , Doença da Membrana Hialina/mortalidade , Doença da Membrana Hialina/terapia , Incidência , Recém-Nascido Prematuro , Intubação Intratraqueal , Doenças do Prematuro/tratamento farmacológico , Doenças do Prematuro/mortalidade , Estimativa de Kaplan-Meier , Pneumopatias/etiologia , Pneumopatias/prevenção & controle , Enfisema Mediastínico/epidemiologia , Enfisema Mediastínico/etiologia , Pneumotórax/epidemiologia , Pneumotórax/etiologia , Complicações na Gravidez/epidemiologia , Estudos Retrospectivos , Risco , Síndrome do Desconforto Respiratório do Recém-Nascido/tratamento farmacológico , Síndrome do Desconforto Respiratório do Recém-Nascido/mortalidade , Sepse/epidemiologia , Resultado do TratamentoRESUMO
Objective To compare the efficacy and safety of a new porcine-derived pulmonary surfactant developed by Instituto Butantan with those of animal-derived surfactants commercially available in Brazil, regarding neonatal mortality and the major complications of prematurity in preterm newborns with birth weight up to 1500g and diagnosed with respiratory distress syndrome. Methods Neonates diagnosed with respiratory distress syndrome were randomized to receive either Butantan surfactant (Butantan group) or one of the following surfactants: Survanta® or Curosurf®. Newborns receiving Survanta® or Curosurf® comprised the control group. The main outcome measures were mortality rates at 72 hours and at 28 days of life; the typical complications of prematurity as evaluated on the 28th day of life were defined as secundary outcomes. Results No differences were observed between the Butantan (n=154) and control (n=173) groups in relation to birth weight, gestational age, sex, and prenatal use of corticosteroids, or in mortality rates both at 72 hours (14.19% versus 14.12%; p=0.98) and at 28 days (39.86% versus 33.33%; p=0.24) of life. Higher 1- and 5-minute Apgar scores were observed among control group newborns. No differences were observed as regards the secondary outcomes, except for greater need for supplemental oxygen and a higher incidence of interstitial pulmonary emphysema in the Butantan group. Conclusion The mortality rates at 72 hours and 28 days of life and the incidence of major complications of prematurity were comparable to those found with the animal-derived surfactants commercially available in Brazil, showing the efficacy and safety of the new surfactant in the treatment of respiratory distress syndrome ...
Objetivo Comparar a eficácia e a segurança de um novo surfactante pulmonar de origem porcina, desenvolvido pelo Instituto Butantan, com os surfactantes de origem animal disponíveis no país, em relação à mortalidade neonatal e às principais complicações da prematuridade, em prematuros com peso de nascimento até 1500g e diagnóstico de síndrome do desconforto respiratório. Métodos Recém-nascidos com diagnóstico de síndrome do desconforto respiratório foram randomizados para receber surfactante Butantan (Grupo Butantan) ou um dos seguintes surfactantes: Survanta® ou Curosurf®. Os recém-nascidos que receberam Survanta® ou Curosurf® formaram o Grupo Controle. Foram definidas, como variáveis primárias, as mortalidades com 72 horas e 28 dias de vida e, como variáveis secundárias, as principais complicações típicas da prematuridade, avaliadas no 28O dia de vida. Resultados Não foram observadas diferenças em relação ao peso de nascimento, idade gestacional, sexo e corticoide pré-natal, assim como em relação à mortalidade dos recém-nascidos dos Grupos Butantan (n=154) e Controle (n=173), tanto com 72 horas (14,19% versus 14,12%; p=0,98) como em 28 dias de vida (39,86% versus 33,33%; p=0,24). Foram observados maiores valores do boletim de Apgar de 1 e de 5 minutos entre os recém-nascidos do Grupo Controle. Os grupos não diferiram em relação às variáveis secundárias, exceto por uma maior necessidade de uso de oxigênio e de enfisema pulmonar intersticial no Grupo Butantan. Conclusão As taxas de mortalidade com 72 horas ...
Assuntos
Feminino , Humanos , Lactente , Recém-Nascido , Masculino , Produtos Biológicos/uso terapêutico , Fosfolipídeos/uso terapêutico , Surfactantes Pulmonares/uso terapêutico , Síndrome do Desconforto Respiratório do Recém-Nascido/tratamento farmacológico , Peso ao Nascer , Método Duplo-Cego , Idade Gestacional , Mortalidade Infantil , Estudos Prospectivos , Reprodutibilidade dos Testes , Síndrome do Desconforto Respiratório do Recém-Nascido/mortalidade , Estatísticas não Paramétricas , Fatores de Tempo , Resultado do TratamentoRESUMO
Resumen Introducción: desde 1990 en que se introdujo en Uruguay la administración del surfactante exógeno para el tratamiento del Síndrome Dificultad Respiratoria (SDR) del recién nacido, el procedimiento se realiza a través de un tubo endotraqueal mientras son ventilados con presión positiva intermitente. Algunos efectos adversos y morbilidad asociada a esta práctica se han adjudicado al uso de la prótesis endotraqueal y sus efectos como cuerpo extraño. A principios de este siglo se propuso usar el tubo endotraqueal exclusivamente para la administración del surfactante, retirándolo inmediatamente después y se le denominó InSurE (Intubation Surfactant Extubation). Recientemente se ha demostrado que la seguridad es mayor si el surfactante se administra en el recién nacido con respiración espontánea, sin asistencia ventilatoria mecánica y a través de un catéter fino guiado por laringoscopia. El catéter se retira al finalizar la administración y se reintroduce para la segunda dosis si es necesario. Por su similitud con otras modalidades de administración de fluidos por catéter (clisis) en nuestro medio se le denomina traqueoclisis (TQ). Objetivo: comunicar la realización de esta técnica en un grupo de recién nacidos en nuestro medio. Reporte de casos: de los registros clínicos se recogieron las características de peso al nacer, perímetro craneano, edad gestacional, administración antenatal de corticoides para inducir maduración pulmonar, vía de nacimiento, puntaje de Apgar, edad a la primera instilación de surfactante, necesidad posterior de intubación orotraqueal y asistencia ventilatoria por tubo endotraqueal, la evolución clínica y radiológica y eventos adversos. Resultados: desde junio 2012 hasta abril 2013 se realizó el procedimiento en 8 recién nacidos con SDR que requirieron soporte respiratorio con presión positiva continua vía nasal (nCPAP). Los pacientes se asistieron en la Unidad de Perinatología Especializada Maternidad del Servicio Médico Integral (UPE-SMI) de Uruguay. Se observó mejoría clínica y radiológica en todos los casos, sin eventos adversos durante el procedimiento, ni fue necesaria su intubación en las primeras 72 horas de vida. Conclusiones: comprobamos la similitud empírica de nuestros resultados con los reportados en otros estudios y series internacionales recientes. La instilación de surfactante por TQ en recién nacidos con SDR apoyados con nCPAP es una nueva modalidad de manejo sencilla y segura.
Summary Introduction: since the introduction of the administration of exogenous surfactant for the treatment of Respiratory Distress Syndrome (RDS) of the newborn infant in Uruguay in1990, the procedure is done through an endotracheal tube while being ventilated with intermittent positive pressure. Some of the adverse effects and morbidity of this procedure may be caused by the tube itself acting as a foreign body. After a decade of use it was proposed to reduce to a minimum the duration of endotracheal tube and this practice is known as InSurE (Intubation Surfactant Extubation). More recently it has been reported that it is safer if the exogenous surfactant is administered through a thin catheter introduced in the trachea guided by laryngoscopy during spontaneous breathing and removed at the end of the administration. For its similarity to other modes of administration of fluids through catheters (clysis) we call it tracheoclysis (TQ). Objective: to report the usage of this technique in a group of preterm infants. Case report: we report the characteristics of these patients as registered in their clinical records: birth weight, head circumference, gestational age, antenatal administration of corticosteroids to induce lung maturation, birth route, Apgar score, age at first instillation of surfactant, subsequent need for endotracheal intubation and ventilatory assistance by endotracheal tube clinical and radiological immediate outcomes and adverse events. Results: from june 2012 to april 2013 the procedure was performed in 8 patients with RDS who required respiratory support via nasal continuous positive airway pressure (nCPAP). Patients were cared at the Unidad de Perinatología Especializada Maternidad of the Servicio Medico Integral (UPE-SMI) of Montevideo, Uruguay. There was clinical and radiological improvement in all cases, no adverse events were observed during the procedure, during the following first 72 hours of life. Conclusions: we empirically corroborated the similarity of our results with those reported in the recent international literature. Administration of surfactant by tracheoclysis in newborns with RDS supported with nCPAP is a new way of simple and safe care, reducing the need endotracheal intubation in the first 72 hours of life.
RESUMO
BACKGROUND: The practice of minimal handling is recommended for preterm infants (PTIs). However, few studies have investigated the effects of this practice among these infants or the time needed to ensure greater physiological stability, especially after exogenous surfactant treatments. OBJECTIVE: The current study compared the effects of two protocols of minimal handling on the physiological variables of PTIs after surfactant therapy. METHOD : An exploratory prospective observational study was performed with 40 PTIs weighing less than 1,500 g. The infants were divided into two groups and monitored for 72 hours. One group received the standard minimal handling procedure during the first 12 hours after surfactant therapy; the other group (i.e., the modified group) received minimal handling within 72 hours after surfactant therapy. Infant heart rate (HR), oxygen saturation, body temperature, and the adverse events associated with changes to these variables were monitored every 10 minutes. RESULTS : Significant between-group differences were not found with regard to the occurrence of the adverse events associated with physiological changes (p>0.05). CONCLUSION: The practice of minimal handling among very low birth weight infants did not alter their physiological stability when performed either 12 or 72 hours after surfactant therapy. .
CONTEXTUALIZAÇÃO: A prática de manuseio mínimo é recomendada a recém-nascidos pré-termo. Contudo, há escassez de estudos, na literatura, sobre os efeitos da utilização dessa prática nesses recém-nascidos e sobre o tempo necessário para garantir maior estabilidade fisiológica a eles, principalmente após terapia com surfactante exógeno. OBJETIVO: Comparar o efeito de dois protocolos de manuseio mínimo em variáveis fisiológicas de recém-nascidos pré-termo após terapia com surfactante. MÉTODO: Foi realizado um estudo observacional prospectivo exploratório com 40 recém-nascidos, menores que 1500g, distribuídos em dois grupos que foram monitorizados e seguidos durante 72 horas. Um grupo permaneceu em manuseio mínimo padrão durante as primeiras 12 horas após surfactante; o outro grupo, denominado grupo modificado, ficou em manuseio mínimo por 72 horas após surfactante. As variáveis de frequência cardíaca, saturação periférica de oxigênio e temperatura axilar e eventos adversos associados a essas variáveis foram monitorados de dez em dez minutos. RESULTADOS: Não houve diferenças significativas na ocorrência de eventos adversos associados às variáveis estudadas, entre os grupos, em relação ao tempo de manuseio mínimo (p>0,05). CONCLUSÃO: A prática de manuseio mínimo em recém-nascidos de muito baixo peso não alterou a estabilidade fisiológica quando executada durante 12 horas ou 72 horas após administração surfactante. .
Assuntos
Feminino , Humanos , Recém-Nascido , Masculino , Terapia Intensiva Neonatal/métodos , Modalidades de Fisioterapia , Surfactantes Pulmonares/uso terapêutico , Respiração Artificial , Protocolos Clínicos , Recém-Nascido Prematuro , Estudos Prospectivos , Fatores de TempoRESUMO
Introducción: desde 1990 en que se introdujo en Uruguay la administración del surfactante exógeno para el tratamiento del Síndrome Dificultad Respiratoria (SDR) del recién nacido, el procedimiento se realiza a través de un tubo endotraqueal mientras son ventilados con presión positiva intermitente. Algunos efectos adversos y morbilidad asociada a esta práctica se han adjudicado al uso de la prótesis endotraqueal y sus efectos como cuerpo extraño. A principios de este siglo se propuso usar el tubo endotraqueal exclusivamente para la administración del surfactante, retirándolo inmediatamente después y se le denominó InSurE (Intubation Surfactant Extubation). Recientemente se ha demostrado que la seguridad es mayor si el surfactante se administra en el recién nacido con respiración espontánea, sin asistencia ventilatoria mecánica y a través de un catéter fino guiado por laringoscopia. El catéter se retira al finalizar la administración y se reintroduce para la segunda dosis si es necesario. Por su similitud con otras modalidades de administración de fluidos por catéter (clisis) en nuestro medio se le denomina traqueoclisis (TQ). Objetivo: comunicar la realización de esta técnica en un grupo de recién nacidos en nuestro medio. Reporte de casos: de los registros clínicos se recogieron las características de peso al nacer, perímetro craneano, edad gestacional, administración antenatal de corticoides para inducir maduración pulmonar, vía de nacimiento, puntaje de Apgar, edad a la primera instilación de surfactante, necesidad posterior de intubación orotraqueal y asistencia ventilatoria por tubo endotraqueal, la evolución clínica y radiológica y eventos adversos. Resultados: desde junio 2012 hasta abril 2013 se realizó el procedimiento en 8 recién nacidos con SDR que requirieron soporte respiratorio con presión positiva continua vía nasal (nCPAP)...